HYUNDAI BIOSCIENCE Co., Ltd.

Ebola IC50 (0.125μM)—Strong inhibition at less than half the concentration of the clinically-tested COVID-19 (0.28μM). Clinical safety confirmed through COVID-19 and Dengue clinical trials. Class-wide efficacy proven by accumulated research data for Hantavirus treatment. Davey Smith, Professor, UC San Diego, "IC50 is a key indicator to estimate clinical efficacy." SEOUL, South Korea, May 20, 2026 /PRNewswire/ -- Hyundai Bioscience announced on May 20th that XAFTY® has a strong likelihood of being able to treat Ebola and Hantavirus given its low IC50 (50% inhibitory concentration) for those viruses. Amid the current crisis of these two often fatal infectious diseases XAFTY® should be considered for testing. Efficacy against Ebola, More Than Double That Against COVID-19— Ready for Immediate Administration The IC50 data is the drug concentration that can inhibit viral replication by 50%. The lower the value, the stronger the antiviral effect with a smaller amount. XAFTY® has as IC50 level of 0.28 μM against SARS-CoV-2, the pathogen in COVID-19, and has already proven its therapeutic efficacy in human COVID-19 clinical trials. The IC50 level of XAFTY® is even lower for the Ebola virus at 0.125 μM. This suggests that XAFTY® could be a promising agent to treat Ebola-infected patients. Safety Proven by COVID-19 Clinical Trials—Immediate Supply Available XAFTY® proved its safety through the COVID-19 Phase 2/3 clinical trials and an ongoing Dengue Phase 2/3 clinical trial in Vietnam. No severe adverse events have been reported so far across all dosage groups, reaffirming its clinical safety. Hyundai Bioscience reports that it has enough drug inventory for immediate supply to the outbreak frontlines. Antiviral Efficacy Against Hantavirus Expected XAFTY® has reported on its broad antiviral activity. It demonstrated exceptional inhibitory efficacy of less than 0.125 μM against the Severe Fever with Thrombocytopenia Syndrome (SFTS) virus, which serves as scientific evidence for activity against Hantavirus. Both SFTS virus and Hantavirus belong to the same virus class. Dr. Davey Smith, University of California-San Diego (UCSD) professor and virologist said, "The clinical efficacy of an antiviral drug may be predicted by its IC50 level against that virus." He added, "XAFTY® is a drug that has already demonstrated safety in humans, and should be strongly considered for Ebola." Dr. Bae Byoungjun, President of Hyundai Bioscience, said, "In a critical outbreak situation, the success or failure of treatment is to be determined not by therapeutic potentials, but by proven efficacy and safety that can be supplied immediately." SOURCE Hyundai Bioscience 21% more press release views with Request a Demo

药品营销避坑”试读： 药品导入期管理视频课（试听） 药品生命周期管理（案例） 药品立项需要注意什么（案例） 2026年5月21日，韩国现代生物Hyundai Bioscience发布了Xafty抑制埃博拉病毒的体外实验数据。 埃博拉病毒（Ebola virus）是引起埃博拉出血热的病原体，病死率高可达50%-90%，于20世纪70年代在非洲首次发现。该病毒能够通过接触、气溶胶、注射途径和性传播多种方式传播，尚无特效治疗药物，主要为对症支持治疗。该实验数据显示Xafty抑制埃博拉病毒的IC50为0.125μM，低于其新型冠状病毒的抑制浓度（IC50为0.28μM）。 Xafty为氯硝柳胺（Niclosamide）-氧化镁（MgO）羟丙基甲基纤维素（HPMC）纳米复合递送系统，有效成分为氯硝柳胺，由于氯硝柳胺口服难以吸收，该纳米复合递送系统有助于提高氯硝柳胺的口服生物利用度。氯硝柳胺原为抗寄生虫药物，体外实验显示氯硝柳胺对多种病毒也具有抑制作用。在抗病毒方面，氯硝柳胺为SKP2（S期激酶相关蛋白2）的抑制剂。SKP2能够使Beclin1通过泛素化降解，Beclin1是调控细胞自噬功能的重要因子，因此抑制SKP2有助于增强细胞的自噬功能，清除病原体。2024年Hyundai Bioscience宣布已向韩国食品药品安全部（MFDS）申请Xafty紧急使用授权（EUA）用于轻中度新型冠状病毒肺炎。 相关阅读： 抗IL-23进入口服时代，翰森发布HS-20118一期临床试验数据 优于利生奇珠单抗，优时比发布比奇珠单抗3期临床数据 抗骨质疏松双膦酸口服月制剂，鲁南米诺膦酸片50mg获批 减重12.4%，闻泰国产口服小分子GLP-1取得3期试验顶线结果 恒瑞HER3 ADC治疗EGFR突变晚期NSCLC三期研究达到终点 康方生物CD47单抗莱法利急性髓系白血病2期研究数据发布 信立泰上市首个特立帕肽周制剂，冲击骨质疏松市场 难治性高血压，FDA批准阿斯利康醛固酮合酶抑制剂Baxdrostat 艾伯维T细胞衔接器双抗艾可瑞妥获批，用于滤泡性淋巴瘤 尿蛋白降幅近60%，荣昌生物发表泰它西普IgA肾病3期研究 首家，苑东生物硫酸吗啡盐酸纳曲酮缓释胶囊申请上市 不反弹？和剂药业合作方发布CPI-818特应性皮炎1期临床数据 国产抗流感新药，众生药业申请上市昂拉地韦儿童颗粒剂型 替尔泊肽5mg可用于减重后维持治疗，礼来公布新研究数据 中国药科大学深圳校友会关于加强医药企业合规经营、促进行业健康发展的倡议书 相关内容只作为药物研发的参信息。不构成任何与用药咨询有关的建议。 如需发稿，您可通过在药研苑公众号下以发送信息的方式将官网或官方公众号的稿件链接和标题发送给我们。我们将择优确定是否发布。

SEOUL, South Korea, May 20, 2026 /PRNewswire/ -- Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus. Hyundai Bioscience said that if the World Health Organization (WHO) or countries affected by infectious disease outbreaks request support for XAFTY®, it can immediately provide products currently in stock. According to the company, niclosamide, the main ingredient of XAFTY®, has previously been reported to have inhibitory effects against Ebola and hantavirus. The company stated, "In the ongoing Phase 2 clinical trial of XAFTY® for dengue fever in Vietnam, no adverse events have been reported so far," and claimed that "in a situation where two viruses are spreading simultaneously, XAFTY® could serve as an effective alternative." Hyundai Bioscience added that, as a member of the Medical CBRN Defense Consortium (MCDC), a U.S. Department of Defense-supported consortium, it will actively cooperate in responding to international public health crises. CONTACT： Jason Kim [email protected] (562) 964-3910 SOURCE Hyundai Bioscience 21% more press release views with Request a Demo